Business
VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP
VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nVALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP\nCanada NewsWire\nMONTREAL, Feb. 2, 2024\n\n\n\n/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/\nOriginal commercialization and supply agreement amended following global divestment of XIIDRA® SIMBRINZA® remains under Valeo Pharma exclusive promotion and distribution Proceeds from reimbursement to be used for debt reduction purposesSagard credit facility amended to provide for early repayments and liquidity requirements in fiscal 2024MONTREAL, Feb. 2, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\"), a Canadian pharmaceutical company, announced today that it has entered into an amendment (the \"Amendment\") of its 7-year Commercialization and Supply Agreement (the \"Commercialization and Supply Agreement\") of XIIDRA® and SIMBRINZA® originally entered into with Novartis Pharmaceuticals Canada Inc. (\"Novartis\") in July 2022. For sake of clarity SIMBRINZA® is a registered trademark of Novartis AG while XIIDRA® is a registered trademark of Bausch and Lomb. The use of both trademarks has been authorized only in the context of this press release.\n\n \n \n \n \n \n \n\n \nAs per the Amendment, Valeo will continue to distribute XIIDRA® for the entire transition period, until certain regulatory transfers have been received by the XIIDRA® global purchaser (''Effective Date of Termination\"). The transition period is expected to continue until approximately Q3-2024.\nValeo will continue to commercialize and promote SIMBRINZA® on an exclusive basis as provided by the Commercial and Supply Agreement with Novartis.\nWithin 60 days from the Effective Date of ...